FDA warns Avertix Medical over Guardian implantable cardiac event detector quality violations and late injury reports.
What happened
FDA inspected Avertix's Eatontown, NJ facility from February 19, 2025, through March 11, 2025. It found the company did not properly handle or investigate complaints, did not reassess device risks after infections and battery failures, did not verify corrective and preventive actions (CAPA), did not address sterilization validation, and did not fully manage suppliers. FDA also found the company reported some serious injuries and malfunctions late or through voluntary MedWatch forms rather than required Medical Device Reporting (MDR) reports.
What FDA found
The company did not maintain complaint files or follow procedures to review and investigate complaints, including infections that led to device removal.
21 CFR 820.198(a), (a)(1), (c)The company's nonconforming product procedure did not require deciding whether an investigation was needed, and two nonconformances had no documented investigation.
21 CFR 820.90(a)The company did not reassess device risks after observed infection and battery-failure rates were higher than the risk file estimates.
21 CFR 820.30(g)The company did not follow its corrective and preventive action (CAPA) procedure and did not verify that several CAPAs were effective.
21 CFR 820.100(a), (a)(4)The company's process validation procedures did not address sterilization validation or requalification for the implantable device.
21 CFR 820.75(a)FDA says serious injuries from infections and malfunctions from early battery depletion were not reported within 30 calendar days as required.
21 CFR 803.50(a)(1), 803.50(a)(2), 803.12(a)
What FDA wants
FDA asks Avertix to correct the cited quality-system and MDR violations, provide adequate corrective actions and supporting evidence, and conduct retrospective reviews; the provided letter does not state a response deadline.
Who should pay attention
- makers of implantable cardiac monitors
- medical device firms with complaint, CAPA, and MDR duties
- companies relying on contract manufacturers and sterilization vendors
This is a summary. Read the original letter on fda.gov.